↑ 疾患リストへ ← 戻る

 278. 巨大リンパ管奇形(頚部顔面病変) [臨床試験数:14,薬物数:15(DrugBank:7),標的遺伝子数:5,標的パスウェイ数:5] 

Searched query = "Huge lymphatic malformation with cervicofacial lesion", "Huge lymphatic malformation", "Lymphatic malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04128722November 15, 201911 November 2019TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUNTOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUNLingual Microcystic Lymphatic MalformationsDrug: Sirolimus Oral Liquid Product 1mg/mLUniversity Hospital, ToursNot recruiting5 YearsN/AAll12Phase 2France
2NCT03972592June 5, 201916 September 2019Topical Sirolimus in Cutaneous Lymphatic Malformations0.1% Topical Sirolimus in the Treatment of Cutaneous Microcystic Lymphatic Malformations in Children and Adults: Phase II, Split-body Randomized, Double-blind, Vehicle-controlled Clinical TrialVascular Malformations;Lymphatic MalformationDrug: Topical 0.1% Sirolimus;Drug: Topical VehicleUniversity Hospital, ToursUniversity Hospital, AngersRecruiting6 YearsN/AAll55Phase 2France
3EUCTR2018-001359-11-FR22/02/201930 April 20190.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial - TOPICALCutaneous microcystic lymphatic malformations (CMLM) in children and adults
MedDRA version: 20.0 Level: LLT Classification code 10003229 Term: Arteriovenous malformations System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Sirolimus 0,1% crème
Pharmaceutical Form: Cream
INN or Proposed INN: SIROLIMUS
CAS Number: 53123-88-9
Concentration unit: % (W/W) percent weight/weight
Concentration type: equal
Concentration number: 0.1-
Pharmaceutical form of the placebo: Cream
Route of administration of the placebo: Cutaneous use
CHRU TOURSAuthorised Female: yes
Male: yes
55Phase 2France
4NCT03243019June 25, 201828 October 2019Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic MalformationsEvaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor PrognosisLymphatic Malformation;PediatricDrug: rapamycin;Device: MRI;Biological: Rapamycin dosageUniversity Hospital, LilleMinistry of Health, FranceRecruiting1 Year18 YearsAll28Phase 2France
5JPRN-jRCTs03118029016/11/20177 October 2019A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomaliesA multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies - Sirolimus for intractable vascular anomaliesIntractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lympha
Vascular disorders
Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
Michio OzekiRecruitingNot applicableNot applicableBoth50Phase 3none
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-UMIN0000305222017/11/142 April 2019A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomaliesIntractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformationsBody surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
Gifu UniversityRecruitingNot applicableNot applicableMale and Female50Not selectedJapan
7JPRN-jRCTs03118026510/08/201610 September 2019Study of bleomycin and OK-432 combined scletotherapy for LMsClinical study of bleomycin and OK-432 combined local injection sclerotherapy for intractable lymphatic malformationsLymphangioma (lymphatic malformation, common or cystic lymphatic malformation), and other lymphatic
lymphangioma, lymphatic malformation,;D18.1
OK-432 and bleomycin slolution (0.05 kE / mL and 0.5 mg / mL, respectively) will be injected into the lesion with water-soluble contrast agent Maximum dose of bleomycin is 10 mg /dose and 5 mg/kgBW.Cumulative maximum dose in repeated treatment is 10 mg/kgBWAkihiro FujinoNot RecruitingNot applicableNot applicableBoth21N/Anone
8NCT02335242May 23, 201515 April 2019Sildenafil for the Treatment of Lymphatic MalformationsPhase 2 Study of Sildenafil for the Treatment of Lymphatic MalformationsLymphatic Malformations;Lymphatic DiseasesDrug: Sildenafil 20 mg tablets;Other: Placebo tablets (resembling Revatio)Stanford UniversityAnn & Robert H Lurie Children's Hospital of ChicagoRecruiting6 Months10 YearsAll40Phase 2United States
9ChiCTR-OPC-160087022014-05-0118 April 2017Efficacy and safety of oral sildenafil in the treatment of pediatric lymphatic malformations in ChinaSildenafil in the treatment of pediatric lymphatic malformationspediatric lymphatic malformationsSildenafil-treated group:oral sildenafil;Beijing Children's HospitalRecruitingBothSildenafil-treated group:40;Pilot studyChina
10JPRN-UMIN0000084982012/07/252 April 2019Propranolol for a treatment of lymphatic malformationlymphatic malformationpropranolol therapyUniversity of TokyoNot RecruitingNot applicable65years-oldMale and Female20Phase 2Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01212965September 201019 February 2015Selenium in the Treatment of Complicated Lymphatic MalformationsPilot Clinical Trial to Estimate the Safety and Efficacy of Selenium in the Treatment of Complicated Lymphatic Malformations in Adolescents and Young AdultsLymphatic MalformationsDrug: SeleniumMedical College of WisconsinNot recruiting14 Years30 YearsBoth5Phase 1United States
12NCT00975819October 200919 February 2015Safety and Efficacy Study of Sirolimus in Complicated Vascular AnomaliesA Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular AnomaliesKaposiform Hemangioendotheliomas;Tufted Angioma;Capillary Venous Lymphatic Malformation;Venous Lymphatic Malformation;Microcystic Lymphatic Malformation;Mucocutaneous Lymphangiomatosis and Thrombocytopenia;Capillary Lymphatic Arterial Venous Malformations;PTEN Overgrowth Syndrome With Vascular Anomaly;Lymphangiectasia SyndromesDrug: sirolimusChildren's Hospital Medical Center, CincinnatiNot recruitingN/A31 YearsBoth60Phase 2United States
13NCT00010452April 20007 April 2015Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic MalformationsTreatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter TrialLymphatic MalformationsDrug: picibanilUniversity of IowaNot recruiting6 Months18 YearsBoth150Phase 2/Phase 3United States
14NCT03427619January 1, 199818 December 2018OK432 (Picibanil) in the Treatment of Lymphatic MalformationsOK432 (Picibanil) in the Treatment of Lymphatic MalformationsLymphatic MalformationsDrug: OK432Richard JH SmithNot recruiting6 Months17 YearsAll701Phase 4United States

先頭へ